Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Med 2021 | SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS

Jo Brewer • 7 Apr 2021
Meeting on the Med 2021
Sarcoma Solid Tumors ADP-A2M4
SPEARHEAD-1

Jo Brewer, PhD, Adaptimmune, Philadelphia, PA, introduces the ongoing Phase II SPEARHEAD-1 trial (NCT04044768), assessing the efficacy and safety of ADP-A2M4 in patients with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS). The ADP-A2M4 SPEAR T-cell therapy targets the MAGE- A4 antigen presented by HLA-A2+ patients. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

More from Jo Brewer

3:06
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs
Jo Brewer • 7 Apr 2021
1:22
SURPASS: evaluating the next-generation of SPEAR T-cell therapy
Jo Brewer • 7 Apr 2021
4:23
Off-the-shelf iPSC therapies for solid tumors
Jo Brewer • 7 Apr 2021
1:28
The potential of iPSCs in cell therapy
Jo Brewer • 7 Apr 2021

Related Videos

1:43
Plasmacytoid dendritic cell-based cancer vaccines
Eric Halioua • 20 Apr 2022
1:34
Assessing PDC*mel, dendritic cell-based vaccine in melanoma
Eric Halioua • 20 Apr 2022
2:41
Developing a therapeutic cancer vaccine for patients with NSCLC
Eric Halioua • 20 Apr 2022
1:13
PiggyBac Transposon-generated CAR T-cells in solid tumors
Shigeki Yagyu • 8 Apr 2022
The content of VJRegenMed is intended for healthcare professionals